Table 3.
Bivariate analyses of mean (SD) differences between T2 and T1 in genetic-specific psychosocial difficulties between test results
| PAHC 1 Hereditary predisposition |
PAHC 2 Familial and social issues |
PAHC 3 Emotions |
PAHC 4 Familial cancer |
PAHC 5 Personal cancer |
PAHC 6 Children-related issues |
|
| Genetic test result | ||||||
| BRCA1/2 pathogenic variant (n=79) | −3.5 (23.1) | 4.9 (17.7) | −0.1 (18.1) | −0.1 (19.6) | 0.9 (22.2) | −2.7 (19.0) |
| Other high/moderate-risk pathogenic variant (n=19) | −2.5 (22.7) | 6.0 (28.3) | −3.2 (20.2) | −6.1 (25.3) | −8.8 (20.3) | −3.7 (21.7) |
| Negative (uninformative) (n=259) | −7.3 (23.2) | −0.2 (17.1) | −1.9 (20.8) | −2.5 (19.8) | −3.3 (25.0) | −7.2 (23.0) |
| Negative (true) (n=44) | −12.9 (24.6) | 4.3 (17.2) | −4.0 (15.4) | 1.4 (20.5) | −11.6 (29.7) | −11.7 (24.3) |
| VUS (n=59) | −18.3 (29.8) | −6.5 (20.7) | −0.7 (25.8) | −3.0 (21.9) | −5.5 (21.3) | −11.9 (23.6) |
| Country | ||||||
| France (n=172) | −5.7 (19.7) | 1.7 (17.8) | 0.5 (18.8) | −3.2 (21.9) | −2.7 (27.3) | −4.8 (23.0) |
| Germany (n=220) | −10.3 (26.6) | −1.5 (18.9) | −2.8 (21.5) | −1.4 (19.7) | −4.4 (20.6) | −10.0 (22.6) |
| Spain (n=68) | −9.5 (28.0) | 4.5 (18.4) | −34 (21.1) | −0.6 (18.9) | −5.2 (29.5) | −5.5 (21.0) |
Notes: T1=assessment after initial genetic consultation; T2=assessment 2 months after receipt of genetic test result. PAHC: score range=0–100, a difference of~10 of the scale range is clinically significant. Overall statistically significant difference between test results on respondents at T1 and at T2: HP and FSI=**p<0.01 and between countries: FSI=**p<0.05.
PAHC, Psychosocial Aspects of Hereditary Cancer; VUS, variants of uncertain significance.